Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Crovalimab vs Eculizumab in PNH Patients on Complement Inhibitors
jRCT2080225334Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety of crovalimab vs eculizumab, Pharmacokinetics of crovalimab and 2 more. Started Aug 2020; status: completed.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2080225334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225334.